Erratum: Ranibizumab and Nonocular Hemorrhage.
Beaumont
Paul E
PE
Kang
H Kwon
HK
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D011358:Product Surveillance, Postmarketing; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab